NCT06999174Recruiting
Multiparametric MRI for Characterization of Hepatocellular Carcinoma
Multiparametric MRI for Optimized Imaging-based Characterization and Therapy Management of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 2 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for hepatocellular carcinoma (HCC). The goal is to evaluate whether advanced MRI parameters can support noninvasive diagnostic assessments and personalized treatment plans for patients with HCC. The study is being conducted at a single university center in Germany and includes adult patients with confirmed or suspected HCC. Participants will undergo standardized multiparametric MRI examinations, and the imaging data will be correlated with clinical, pathological, and therapeutic outcomes. No study-specific interventions or medications will be administered.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 128 (estimated)
- First submitted
- 22 May 2025
- Start date
- 1 May 2025
- Primary completion date
- 1 May 2027
- Lead sponsor
- University Hospital Muenster
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06999174
What you commit to
- Study type: Observational
- Planned participants: 128
- From 1 May 2025 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to MRI (e.g., pacemakers, ferromagnetic implants, severe claustrophobia)
Other illness
- Known allergy or intolerance to gadolinium-based contrast agents
Lab values
- Renal insufficiency with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²
Other
- Pregnancy or breastfeeding
- Inability to provide informed consent
Who the study is looking for
- Age ≥18 years
- Confirmed or suspected diagnosis of HCC
- Scheduled to receive TACE or SIRT as part of standard clinical care
- Eligibility for liver MRI
- Willing and able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinic of Radiology, University of Münster Coordinator of this site? Confirm its status | Münster | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.